Heart Risks, Provider Misconduct, and a 21-Year-Old’s Death Sharpen Safety Warnings as FDA Weighs Psychedelic Care

Testimony at the FDA psychedelic hearing flagged heart risks, screening gaps, and provider misconduct. What families should know before any approval.

Have A Referral?